Alyeska Investment Group L.P. Has $1.58 Million Position in Health Catalyst, Inc. $HCAT

Key Points

• Alyeska Investment Group L.P. significantly reduced its stake in Health Catalyst by 82.7% in Q1, selling over 1.6 million shares.
• Health Catalyst's stock has experienced fluctuations, currently trading at $3.38, with a 52-week range of $2.52 to $9.24.
• Several research firms have revised their target prices for the stock, with estimates ranging from $3.00 to $10.00 as analysts generally maintain a "Hold" rating.

Alyeska Investment Group L.P. trimmed its stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 82.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 349,194 shares of the company's stock after selling 1,670,186 shares during the period. Alyeska Investment Group L.P. owned about 0.50% of Health Catalyst worth $1,582,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its holdings in shares of Health Catalyst by 17.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,591,565 shares of the company's stock worth $11,252,000 after purchasing an additional 235,686 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock valued at $442,000 after purchasing an additional 4,798 shares during the last quarter. Northern Trust Corp boosted its position in Health Catalyst by 8.5% in the fourth quarter. Northern Trust Corp now owns 526,607 shares of the company's stock valued at $3,723,000 after buying an additional 41,298 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Health Catalyst during the fourth quarter worth about $735,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Health Catalyst during the fourth quarter worth approximately $92,000. 85.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on HCAT shares. Stifel Nicolaus reduced their target price on Health Catalyst from $5.50 to $4.50 and set a "hold" rating on the stock in a report on Friday, August 8th. Citigroup lowered Health Catalyst from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $6.50 to $3.50 in a research note on Friday, August 8th. Evercore ISI increased their target price on Health Catalyst from $3.00 to $4.00 and gave the stock an "in-line" rating in a report on Thursday, August 28th. Canaccord Genuity Group lowered their target price on Health Catalyst from $9.00 to $5.00 and set a "buy" rating for the company in a research note on Friday, August 29th. Finally, Piper Sandler downgraded shares of Health Catalyst from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $8.00 to $4.00 in a research report on Wednesday, August 27th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $4.73.

Health Catalyst Trading Down 0.6%

Shares of HCAT traded down $0.02 during trading hours on Thursday, reaching $3.24. The stock had a trading volume of 566,293 shares, compared to its average volume of 872,961. The company has a market cap of $228.00 million, a P/E ratio of -2.15 and a beta of 1.53. Health Catalyst, Inc. has a 52 week low of $2.52 and a 52 week high of $9.24. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average of $3.53 and a 200 day moving average of $3.88.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.